{"id":18009,"date":"2022-02-08T09:09:35","date_gmt":"2022-02-08T09:09:35","guid":{"rendered":"https:\/\/zeepedia.com\/?p=18009"},"modified":"2022-02-09T09:49:20","modified_gmt":"2022-02-09T09:49:20","slug":"minjuvi","status":"publish","type":"post","link":"https:\/\/zeepedia.com\/medical\/medicines\/minjuvi\/","title":{"rendered":"MINJUVI &#8211; Tafasitamab uses, dose and side effects"},"content":{"rendered":"\n<p>200 mg&nbsp;powder for concentrate for&nbsp;solution for&nbsp;infusion<br>tafasitamab<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What MINJUVI is and what it is used for<\/h2>\n\n\n\n<p><strong>What MINJUVI is<\/strong><\/p>\n\n\n\n<p>MINJUVI contains the active substance tafasitamab.\u00a0This is a type of\u00a0protein\u00a0called a monoclonal\u00a0antibody\u00a0and is designed to kill cancer cells.\u00a0This\u00a0protein\u00a0works by attaching to a specific target on the surface of white blood cells called B cells or B\u00a0lymphocytes.\u00a0When tafasitamab attaches to the surface of these cells, the cells die.<\/p>\n\n\n\n<p><strong>What MINJUVI is used for<\/strong><\/p>\n\n\n\n<p>MINJUVI is used to treat adults with B-cell-type cancer called diffuse large-cell B-cell lymphoma.\u00a0It is used when cancer has returned after previous treatment when previous treatment has not had (sufficient) effect and for patients who cannot be treated with\u00a0stem cell transplantation\u00a0instead.<\/p>\n\n\n\n<p><strong>Other medicines that MINJUVI is given with<\/strong><\/p>\n\n\n\n<p>Minjuvi is used together with another cancer medicine, lenalidomide, at the beginning of treatment.&nbsp;Thereafter, the \u2011treatment proceeds with only MINJUVI.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What you need to know before using MINJUVI<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Do not use MINJUVI<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>if you are allergic to tafasitamab or any of the other ingredients of this medicine (listed in section 6).<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Warnings and cautions<\/h2>\n\n\n\n<p>Talk to your doctor or pharmacist before using MINJUVI, if you have an&nbsp;infection&nbsp;or if you have had a recurrent&nbsp;infection&nbsp;before.<\/p>\n\n\n\n<p>You may experience the following during treatment with Minjuvi:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Infusion-related reactions<\/strong><br>Infusion-related reactions may occur most frequently during the first&nbsp;infusion&nbsp;.&nbsp;Your doctor will tell you if you get any infusion-related reactions during your MINJUVI\u2011&nbsp;infusion&nbsp;.&nbsp;Tell your doctor immediately if you get any reactions such as fever, chills,&nbsp;redness&nbsp;, rash or difficulty breathing within 24 hours after the&nbsp;infusion&nbsp;.<br>Your doctor will treat you before each&nbsp;infusion&nbsp;to reduce the risk of infusion-related reactions.&nbsp;If you do not get any reactions, your doctor may decide that you do not need these medicines for later&nbsp;infusions&nbsp;.<\/li><li><strong>Reduced blood cell<br><\/strong>counts Treatment with MINJUVI can seriously reduce the amount of certain types of blood cells in your body, such as blood cells called&nbsp;neutrophils&nbsp;,&nbsp;platelets&nbsp;or&nbsp;red blood cells&nbsp;.&nbsp;Tell your doctor immediately if you develop a fever of 38 \u00b0 C or higher, or signs of bruising or bleeding, as this may indicate a decrease.<br>Your doctor will check the number of blood cells throughout the treatment and before starting any new treatment cycle.<\/li><li><strong>Infection&nbsp;Er<br><\/strong>Serious&nbsp;infections&nbsp;, including&nbsp;infections&nbsp;that can be fatal, can occur during and after MINJUVI treatment.&nbsp;Tell your doctor if you notice signs of&nbsp;infection&nbsp;, such as fever of 38 \u00b0 C or higher, chills, cough or pain when urinating.<\/li><li><strong>Tumor light syndrome<br><\/strong>Some people may develop unusually high levels of certain substances (such as&nbsp;potassium&nbsp;and&nbsp;uric acid&nbsp;) in their blood during treatment because the cancer cells break down so quickly.&nbsp;This is called tumor lysis syndrome.&nbsp;Tell your doctor if you experience symptoms such as nausea, vomiting, poor appetite or fatigue, dark urine, decreased urine output or pain in the side or back, muscle cramps, numbness or palpitations.&nbsp;Your doctor will treat you before each&nbsp;infusion&nbsp;to reduce the risk of tumor lysis syndrome and take blood samples to check if you have tumor lysis syndrome.<\/li><\/ul>\n\n\n\n<p>Tell your doctor immediately if you experience any serious\u00a0side effects.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Children and young people<\/h2>\n\n\n\n<p>MINJUVI is not recommended for children and adolescents under 18 years of age, as there is no information on use in these groups.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Other medicines and MINJUVI<\/h2>\n\n\n\n<p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.<\/p>\n\n\n\n<p>The use of live vaccines during treatment with tafasitamab is not recommended.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pregnancy and breastfeeding<\/h2>\n\n\n\n<p>If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Contraceptives<\/strong><br>Fertile women are advised to use effective contraception during treatment with MINJUVI and for up to at least 3 months after stopping treatment.<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Pregnancy<\/strong><br>Do not use MINJUVI during pregnancy, even if you are a&nbsp;fertile&nbsp;woman who is not using contraception.&nbsp;Pregnancy must be ruled out before starting treatment.&nbsp;Tell your doctor immediately if you become pregnant or think you may be pregnant during treatment with MINJUVI.<br><br>MINJUVI is given with lenalidomide for up to 12 cycles.&nbsp;<strong>Lenalidomide can harm the unborn fetus and should not be used during pregnancy or by fertile women<\/strong>&nbsp;, unless all the conditions of lenalidomide&#8217;s pregnancy prevention program are met.&nbsp;Your doctor will give you more information and recommendations.<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Breast-feeding<br><\/strong>Do not breast-feed during treatment with MINJUVI and for at least three months after the last&nbsp;dose&nbsp;.&nbsp;It is not known whether tafasitamab is excreted in human milk.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Driving and using machines<\/h2>\n\n\n\n<p>MINJUVI has no or negligible effect on the ability to drive and use machines.&nbsp;However, fatigue has been reported in patients taking tafasitamab and this should be considered when driving or using machines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">MINJUVI contains sodium<\/h2>\n\n\n\n<p>This medicine contains 37.0 mg\u00a0sodium\u00a0(the main ingredient in table salt\/table salt) in each\u00a0dose\u00a0of 5 vials (\u00a0dose\u00a0one to one patient of 83 kg).\u00a0This corresponds to 1.85% of the maximum recommended daily\u00a0sodium\u00a0intake for adults.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How to use MINJUVI<\/h2>\n\n\n\n<p>A doctor with experience in cancer treatment will review your treatment.\u00a0MINJUVI will be given into one of your veins via\u00a0infusion\u00a0(drip).\u00a0During and after\u00a0infusion\u00a0one, you will be regularly checked for infusion-related\u00a0side effects.<\/p>\n\n\n\n<p>MINJUVI will be given to you in cycles of 28 days.&nbsp;The dose&nbsp;you receive is based on your weight and will be decided by your doctor.<\/p>\n\n\n\n<p>The recommended&nbsp;dose&nbsp;is 12 mg tafasitamab per kilogram body weight.&nbsp;The drug is given as an&nbsp;infusion&nbsp;into a vein according to the following schedule:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Cycle 1:&nbsp;infusion&nbsp;day 1, 4, 8, 15 and 22 of the cycle<\/li><li>Cycle 2 and 3:&nbsp;infusion&nbsp;day 1, 8, 15 and 22 of each cycle<\/li><li>Cycle 4 and onwards:&nbsp;infusion&nbsp;day 1 and day 15 of each cycle<\/li><\/ul>\n\n\n\n<p>Your doctor will also prescribe lenalidomide capsules for up to twelve cycles.&nbsp;The recommended starting dose of lenalidomide is 25 mg daily on days 1 to 21 of each cycle.<\/p>\n\n\n\n<p>Your doctor will adjust the starting dose and subsequent&nbsp;dose&nbsp;as needed.<\/p>\n\n\n\n<p>Treatment with lenalidomide is discontinued after a maximum of twelve cycles of combination therapy.\u00a0Treatment cycles with MINJUVI alone then continue until the disease worsens or you get unacceptable\u00a0side effects.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">If you have received more MINJUVI than you should<\/h2>\n\n\n\n<p>Because the medicine is given in a hospital under the supervision of a doctor, an overdose is unlikely.&nbsp;Tell your doctor if you think you may have received too much MINJUVI.<\/p>\n\n\n\n<p>If you have any further questions on the use of this product, ask your doctor or pharmacist.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Possible side effects<\/h2>\n\n\n\n<p>Like all medicines, this medicine can cause\u00a0side effects, although not everybody gets them.<\/p>\n\n\n\n<p><strong>Contact<\/strong>&nbsp;your doctor or nurse immediately if you notice any of the following serious&nbsp;side effects&nbsp;&#8211; you may need urgent treatment.&nbsp;These can be new symptoms or a change in your current symptoms.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>severe&nbsp;infection&nbsp;, possible symptoms: fever, chills, sore throat, cough, shortness of breath, nausea, vomiting, diarrhea.&nbsp;These symptoms can be especially pronounced if you have been told that you have low levels of&nbsp;white blood cells&nbsp;called&nbsp;neutrophils&nbsp;.<\/li><li>pneumonia&nbsp;(&nbsp;pneumonia&nbsp;)<\/li><li>sepsis&nbsp;(blood infection)<\/li><\/ul>\n\n\n\n<p><strong>Other&nbsp;side effects&nbsp;are<\/strong><\/p>\n\n\n\n<p>Tell your doctor or nurse if you notice any of the following side effects:<\/p>\n\n\n\n<p><strong>Very common<\/strong>&nbsp;(may affect more than 1 in 10 people)<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>decreased number of&nbsp;blood&nbsp;cells<ul><li>white blood cells&nbsp;, especially of the type known as&nbsp;neutrophils&nbsp;, possible symptoms: fever of 38 \u00b0 C or higher, or other symptoms of&nbsp;infection<\/li><li>platelets;&nbsp;Possible symptoms: unusual bruising or bleeding, which occurred without injury or minor damage<\/li><li>Red blood cells;&nbsp;Possible symptoms: pale skin or lips, fatigue, shortness of breath<\/li><\/ul><\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li>infection&nbsp;is caused by bacteria,&nbsp;viruses&nbsp;or fungi, such as respiratory infections,&nbsp;tracheal catarrh&nbsp;,&nbsp;pneumonia&nbsp;, urinary tract infection<\/li><li>rash<\/li><li>low potassium content in the blood (seen during blood tests)<\/li><li>muscle cramps<\/li><li>back pain<\/li><li>swelling in arms and \/ or legs due to fluid retention<\/li><li>weakness, fatigue, general malaise<\/li><li>fever<\/li><li>diarrhea<\/li><li>constipation<\/li><li>abdominal pain<\/li><li>nausea<\/li><li>vomiting<\/li><li>cough<\/li><li>respiratory distress<\/li><li>decreased appetite<\/li><\/ul>\n\n\n\n<p><strong>Common<\/strong>&nbsp;(may affect up to 1 in 10 people)<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>increased respiratory distress in people with narrow airways, so-called&nbsp;chronic&nbsp;obstructive airways disease&nbsp;(COPD)<\/li><li>headache<\/li><li>abnormal sensation in the skin, such as ant crawls, tingling, numbness<\/li><li>itching<\/li><li>reddening of the skin<\/li><li>infusion-related reactions<br>These may occur during&nbsp;infusion&nbsp;of Minjuvi or within 24 hours after&nbsp;infusion&nbsp;.&nbsp;Possible symptoms are fever, chills,&nbsp;redness&nbsp;and difficulty breathing.<\/li><li>changed taste<\/li><li>hair loss<\/li><li>abnormal sweating<\/li><li>pain in the arms and legs<\/li><li>muscle\u2011 and joint pain<\/li><li>weight loss<\/li><li>nasal congestion<\/li><li>inflammation&nbsp;of the mucous membranes, eg in the oral mucosa<\/li><li>deficiency of certain&nbsp;white blood cells&nbsp;called&nbsp;lymphocytes&nbsp;(seen in blood tests)<\/li><li>problems with the immune system called&nbsp;hypogammaglobulinemia<\/li><li>in blood tests, low levels of<ul><li>calcium<\/li><li>magnesium<\/li><\/ul><\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li>in blood tests, increased levels of<ul><li>C \u2011 reactive&nbsp;protein&nbsp;, which may be due to&nbsp;inflammation&nbsp;or&nbsp;infection<\/li><li>creatinine&nbsp;, a breakdown product of muscle tissue<\/li><li>liver enzyme: gamma glutamyltransferase,&nbsp;transaminase&nbsp;er<\/li><li>bilirubin&nbsp;, a yellow breakdown agent from blood pigments<\/li><\/ul><\/li><li>a skin cancer called basal cell carcinoma<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">How to store MINJUVI<\/h2>\n\n\n\n<p>Keep this medicine out of the sight and reach of children.<\/p>\n\n\n\n<p>Do not use this medicine after the expiry date which is stated on the bottle label and the carton after EXP.\u00a0The expiration date is the last day of the specified month.<\/p>\n\n\n\n<p>Store in a refrigerator (2 \u00b0 C &#8211; 8 \u00b0 C).<\/p>\n\n\n\n<p>Keep the vial in the outer carton.&nbsp;Sensitive to light.<\/p>\n\n\n\n<p>Any unused product or waste material should be disposed of per local requirements.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Contents of the package and other information<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Content declaration<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>The active substance is tafasitamab.&nbsp;One&nbsp;vial&nbsp;contains 200 mg tafasitamab.&nbsp;After&nbsp;reconstitution&nbsp;, each ml of solution contains 40 mg tafasitamab.<\/li><li>The other ingredients are sodium citrate dihydrate, citric acid monohydrate, trehalose dihydrate, polysorbate 20 (see section 2 \u201cMinjuvi contains sodium\u201d).<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What the medicine looks like and contents of the pack<\/h2>\n\n\n\n<p>MINJUVI is a powder for concentrate for solution for\u00a0infusion.\u00a0It is a white to slightly yellowish powder in a clear glass\u00a0vial\u00a0with a rubber stopper, aluminum seal, and plastic cap.<\/p>\n\n\n\n<p>Each carton contains 1\u00a0vial.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Marketing Authorization Holder and Manufacturer<\/h2>\n\n\n\n<p><strong>Marketing Authorisation Holder<\/strong><\/p>\n\n\n\n<p>Incyte Biosciences Distribution BV<\/p>\n\n\n\n<p>Paasheuvelweg 25<\/p>\n\n\n\n<p>1105 BP Amsterdam<\/p>\n\n\n\n<p>Netherlands<\/p>\n\n\n\n<p><strong>Manufacturer<\/strong><\/p>\n\n\n\n<p>MorphoSys AG<\/p>\n\n\n\n<p>Semmelweis.\u00a07<\/p>\n\n\n\n<p>82152 Planegg<\/p>\n\n\n\n<p>Germany<\/p>\n\n\n\n<p>This medicine has been authorized according to the rules of &#8220;conditional marketing authorization&#8221;.&nbsp;This means that more information about the drug is expected.<\/p>\n\n\n\n<p>The European Medicines Agency reviews new information on this medicine at least every year and updates this leaflet as needed.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MINJUVI contains the active substance tafasitamab. This is a type of protein called a monoclonal antibody and is designed to kill cancer cells. This protein works by attaching to a specific target on the surface of white blood cells called B cells or B lymphocytes . When tafasitamab attaches to the surface of these cells, the cells die.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2200,15580],"tags":[17635,17630,17631,17634,17626,17629,17632,17627,17633,17628],"class_list":["post-18009","post","type-post","status-publish","format-standard","hentry","category-medicines","category-m","tag-benefits-of-minjuvi","tag-benefits-of-tafasitamab","tag-minjuvi","tag-minjuvi-side-effects","tag-tafasitamab","tag-tafasitamab-side-effects","tag-what-is-minjuvi","tag-what-is-tafasitamab","tag-what-minjuvi-is-used-for","tag-what-tafasitamab-is-used-for"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/18009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=18009"}],"version-history":[{"count":4,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/18009\/revisions"}],"predecessor-version":[{"id":18053,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/18009\/revisions\/18053"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=18009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=18009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=18009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}